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Immunity and the carotid body:
implications for metabolic diseases
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Abstract
Neuro-immune communication has gained enormous interest in recent years due to increasing knowledge of the way
in which the brain coordinates functional alterations in inflammatory and autoimmune responses, and the mechanisms
of neuron-immune cell interactions in the context of metabolic diseases such as obesity and type 2 diabetes. In this
review, we will explain how this relationship between the nervous and immune system impacts the pro- and anti-
inflammatory pathways with specific reference to the hypothalamus-pituitary-adrenal gland axis and the vagal reflex
and will explore the possible involvement of the carotid body (CB) in the neural control of inflammation. We will also
highlight the mechanisms of vagal anti-inflammatory reflex control of immunity and metabolism, and the
consequences of functional disarrangement of this reflex in settlement and development of metabolic diseases, with
special attention to obesity and type 2 diabetes. Additionally, the role of CB in the interplay between metabolism and
immune responses will be discussed, with specific reference to the different stimuli that promote CB activation and the
balance between sympathetic and parasympathetic in this context. In doing so, we clarify the multivarious neuronal
reflexes that coordinate tissue-specific responses (gut, pancreas, adipose tissue and liver) critical to metabolic control,
and metabolic disease settlement and development. In the final section, we will summarize how electrical modulation
of the carotid sinus nerve may be utilized to adjust these reflex responses and thus control inflammation and
metabolic diseases, envisioning new therapeutics horizons.
Keywords: Carotid body, Carotid sinus nerve, Vagus nerve, Parasympathetic nervous system, Sympathetic nervous
system, Immunity, Inflammation, Metabolic disease
Background
“Neuroinflammation” is a term that generally describes
the innate immune inflammatory response generated in
the central nervous system (CNS) after injury (Kennedy
and Silver 2016). However, in addition some evidences
suggest that this brain-immune axis integrates inputs
from peripheral neuronal networks to inform immune
cells on whole body immune status (Jakob et al. 2020).
In the brain, astrocytes and microglia contribute to
homeostasis by supporting not only neuronal function,
but also immunological responses such as pathogen de-
struction and the removal of dead neurons. In fact, as-
trocytes and microglia are the most abundant producers
of cytokines in the brain (Kennedy and Silver 2016). It
was presumed that these central inflammatory responses
occurred in isolation due to their separation from the
periphery by the blood-brain-barrier (BBB) (Coceani
et al. 1988). However, it is now generally accepted that
CNS communicates with the peripheral immune system
through both neural and humoral mechanisms (Kennedy
and Silver 2016). Moreover, the discovery of the circum-
ventricular organs (CVOs) revealed further immune-to-
brain communication pathways (Blatteis et al. 1987; Stitt
1990). These CVOs have a leaky BBB, and are situated
near the CNS areas that react to peripheral immune
challenges, such as the area postrema (AP) and the or-
ganum vasculosum, which project into the nucleus trac-
tus solitarii (NTS) (Cai et al. 1996). NTS contributes to
immunomodulatory functions that regulate fever,
breathing and autonomic efferent activity to the
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cardiovascular system, and other peripheral systems
(Zoccal et al. 2014).
Impairment of the immune responses by the brain has
also been identified as a contributing factor in the disar-
rangement of inflammatory processes and thus disease
development. In fact, exacerbated inflammation in the
brain is involved in type 2 diabetes, obesity, neurodegen-
erative diseases and many others highly incident diseases
(Ferreira et al. 2014; Jais and Brüning 2017; Terrando
and Pavlov 2018). Adding to this, the neuro-immune
link in the periphery and its dysregulation in inflamma-
tory states such as chronic inflammatory illness, ageing
and metabolic diseases, and the process of integration of
related peripheral inputs in the CNS are emerging as po-
tential mechanisms of disease and thus targets for ther-
apy. For example, metabolic diseases are associated with
chronic “inflammation”, which is characterized by ab-
normal cytokine production, increased acute-phase reac-
tants and other mediators, and activation of a network
of inflammatory signaling pathways. Allied to this, meta-
bolic thermogenesis, blood pressure regulation and in-
testinal motility are modulated through interactions
between sensory nerves, autonomic nervous system, cen-
tral neural regulators and immune cells (Ordovas-Mon-
tanes et al. 2015). In this context, catecholamines
derived from macrophages and norepinephrine (NE) re-
leased from efferent sympathetic nerves promote
thermoregulation by brown adipose tissue (BAT), by ac-
tivating on adrenergic receptors (ARs) of brown adipo-
cytes, that in turn increase expression of uncoupling
protein-1 (UCP1) (Nguyen et al. 2011).
In the present review we will focus on the circuits and
mechanisms involved by which the brain and peripheral
nervous system communicate with the immune system,
giving special attention to this relationship in the con-
text of metabolic disease settlement and development.
The nervous and immune systems
The nervous system is composed of the CNS (the brain
and the spinal cord) and the peripheral nervous system.
The peripheral nervous system has somatic and auto-
nomic components. Somatic nerves originate in the
CNS, innervate skeletal muscles, and provide voluntary
control of movements. The autonomic nervous system
has 3 branches: the sympathetic branch originated in the
thoracic and lumbar areas of the spinal cord, the para-
sympathetic branch originated in the cranial nerves and
sacral spinal cord, and the enteric system originated in
two types of ganglia located in the gastrointestinal tract
(Pavlov et al. 2018).
The sympathetic neurons synapse with relatively long
postganglionic fibers that innervate blood vessels,
lymphoid tissue and organs, bone marrow, joints, spleen,
lungs and airways, gastrointestinal tract, liver, kidneys,
and other visceral organs (Elenkov et al. 2000; Jänig
2014).
The parasympathetic branch of the autonomic nervous
system, the main nerve of which is the vagus, innervates
peripheral viscera. The vagus nerve, whose cell bodies
reside in the dorsal motor nucleus of the vagus (DMN)
and the nucleus ambiguous in the brainstem medulla
oblongata, innervate the visceral organs, including the
lungs, heart, liver, gastrointestinal tract, kidneys and
pancreas, and form synaptic contacts with postgangli-
onic neurons in proximal to or within these organs
(Jänig et al. 2017).
The enteric nervous system is a quasi autonomous
part of the nervous system, with neural circuits localized
in the gut that coordinate gastrointestinal functions
(Goyal and Hirano 1996).
The communication between central and peripheral
nervous systems occurs in both ways, with efferents
nerves bringing information to the periphery and affer-
ent nerves transmitting information from the periphery
to the CNS. The vagus nerves are one of the most im-
portant afferent nerves and innervate the lungs, heart,
gastrointestinal tract, liver, and pancreas and project
centrally to the NTS in the brainstem medulla oblongata
of the CNS (Fernandez et al. 2014; Mazzone and Undem
2016) (Fig. 1).
In this review we will also discuss the immune system,
which is composed by the innate and the adaptive divi-
sions. Innate immune system constitutes the first
defense barrier against foreign organisms. In contrast,
the adaptive immune system shows a delayed response
but at same time presents highly efficient mechanisms to
eliminate pathogens and maintain tolerance to a next
contact to those pathogens (Pacheco et al. 2012).
T-cells are the central players in the adaptive immune
response and are the main promoters of cytokine pro-
duction. These cytokines will then promote or potentiate
functions of other immune cells such as macrophages,
dendritic cells (DCs), and natural killer (NK) cells
(Pacheco et al. 2012). There is a growing evidence that
some cells from the adaptive immune system, specially
the T-cells, constitute an important link between the
nervous system and the immune system (Mignini et al.
2003). This aids in the regulation of nervous system
functions such as acquisition of memory, behavior,
neurogenesis, and may contribute to many neurodegen-
erative disorders (Yirmiya and Goshen 2011). This link
is reciprocal, as data suggest that T-cells and the wider
immune system can be regulated by neurotransmitters
(Franco et al. 2007).
Several receptors for neurotransmitters classically
expressed in both the central and peripheral nervous
system are also expressed on the surface of immune sys-
tem cells. For instance, T-cells and DCs express some
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subtypes of glutamate receptors, acetylcholine receptors
(AChRs), serotonin receptors, dopamine receptors, ARs,
and others (Pacheco et al. 2010). Many other studies
show that neurotransmitter signals modulate the im-
mune response (Glaser and Kiecolt-Glaser 2005). For ex-
ample, Tracey et al. have demonstrated that activation of
α7 nicotinic ACh receptor (α7nAChR) on the macro-
phages inhibits pro-inflammatory cytokines release (Fig.
1) (Andersson and Tracey 2012), which they named the
cholinergic anti-inflammatory pathway (Bonaz et al.
2016; Borovikova et al. 2000). Also, β2-ARs have been
shown to be significantly involved in the modulation of
the immune system, as administration of exogenous β2-
AR agonist, salbutamol, impairs CD8+ priming by cross-
presenting DC in mice (Hervé et al. 2013).
Additionally, both anti-inflammatory and pro-
inflammatory pathways can be modified in experimental
animals by adjusting animal behavior patterns and thus
neurotransmitter levels (Cohen et al. 1994).
Cytokines, the main soluble molecules mediating regu-
latory communications between immune cells, use re-
ceptors for cell-to-cell communication that in the past
were solely assigned to immune regulation, including
pattern recognition receptors (such as toll-like receptors
(TLRs)) and receptors for tumor necrosis factor (TNF),
interleukin-1beta (IL-1β), and other cytokines. However,
Fig. 1 Neuronal reflexes controlling inflammation. The HPA axis is activated by several stimuli to activate the paraventricular nucleus (PVN) of the
hypothalamus leading to the release of cortisol releasing hormone (CRH) into the anterior pituitary. In turn, CRH induces the release of
adrenocorticotrophic hormone (ACTH) in blood, which stimulate the production of glucocorticoids (GC) by the cortex of the adrenal glands,
which are potent anti-inflammatory molecules whose effect is mediated by the signaling via glucocorticoid receptor (GR), a nuclear receptor
expressed by almost all cells in the body and in particular in innate immune cells; Vagal anti-inflammatory reflex is characterized by peripheral
vagal afferent nerves detecting inflammation and sending this information to the CNS. Reciprocal connections between the NTS and DMN
mediate communication with and activation of efferent vagus nerve fibers inducing the release of ACh and ultimately attenuating cytokine
production and inflammation through a mechanism, based on the binding of ACh on nicotinic α7nAChR; Additionally, these cytokines can also
activate directly this region in the brain by a humoral control in order to revert inflammation; Sympathetic fibers originating in the spinal cord
terminate innervate directly visceral organs and immune cells and release norepinephrine (NE) that binds to its specific receptors on these cells.
Efferent sympathetic output to the adrenal gland induces the secretion of epinephrine (EP) from chromaffin cells that circulates in blood to reach
specific receptors in immune cells. EN and NE joint action stops inflammation and release of inflammatory cytokines; finally, inflammation
resolution also occurs through carotid body (CB) action. Briefly, released inflammatory mediators by immune cells activate the CB, which in turn
activates carotid sinus nerve (CSN) that projects within the nucleus tractus solitarii (NTS)
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these receptors have now been shown to be present on
sensory neurons (de Lartigue et al. 2011; Steinberg et al.
2016). Quan et al. also showed that the direct adminis-
tration of many cytokines in the brain promotes regula-
tion of whole-body inflammation (Quan 2014). For
example, IL-1, interferon-gamma (IFN-γ) or TNF-α in-
jection in the brain induced leukocyte infiltration (Ching
et al. 2005) while peripheral lipopolysaccharide (LPS) in-
jection induced the expression of IL-1 in the CNS with-
out affecting the entry of leukocytes in the brain (Ching
et al. 2006). These and many other studies led to the
proposal that peripheral sensory nerves report on in-
flammation status to the brain and vice-versa (Fernández
et al. 2011; Watkins et al. 1995).
Immune cell activation and consequent inflammation
is a protective mechanism. However, pro-inflammatory
cytokines may also cause tissue injury and have deleteri-
ous effects. This occurs, for example, in cases of
Immune-Mediated Inflammatory Diseases (IMIDs) such
as rheumatoid arthritis (RA), inflammatory bowel disease
(IBD) and Systemic Lupus Erythematosus (SLE) (Bradley
2008). Also, many neurodegenerative disorders are asso-
ciated with dysregulated inflammatory processes. Nu-
merous studies have shown that Alzheimer’s and
Parkinson’s disease are accompanied by excessive levels
of pro-inflammatory cytokines in both the peripheral
nervous system and brain (Guzman-Martinez et al.
2019). Additionally, persistent or exaggerated inflamma-
tory pathway activation has been connected to the most
significant metabolic diseases such as type 2 diabetes,
obesity, insulin resistance and other metabolic patholo-
gies, which we will focus on here. One of the organs that
have been considered to underlie the inflammatory re-
sponse associated with metabolic and associated cardio-
vascular diseases is the white adipose tissue (WAT), and
in particular the visceral WAT (Hajer et al. 2008). The
visceral WAT secretes pro-inflammatory cytokines, such
as Interleukin 6 (IL-6), IL-8, MCP-1, PAI-1, as well as
complement factors and substances involved in systemic
acute phase response and innate immunity (Lee and
Fried 2010). During obesity there is an increase in the
number of macrophages within the tissue, which are the
source of TNF-α and other pro-inflammatory cytokines
(Weisberg et al. 2003). For example, TNFα increases in
adipose tissue promotes insulin resistance through serine
phosphorylation of insulin receptor substrate 1 (Hotami-
sligil et al. 1996; Schenk et al. 2008). Also, these WAT-
derived cytokines will modulate brain activity both dir-
ectly by reaching the organ (Thaler et al. 2012) and
through modulation of peripheral neuronal networks
that send information on metabolic status to the CNS
(Pirzgalska and Domingos 2018). Therefore, alterations
in the metabolic information that reaches the CNS will
in turn influence metabolic disease settlement and
progression, associated with type 2 diabetes and non-
alcoholic fatty liver disease, among others (Chait and
den Hartigh 2020).
Moreover, adipocytes are the origin of chemokines
and metabolically active mediators called adipokines.
The adipokines, including adiponectin and leptin, have
been demonstrated to signal through the hypothalamus
to control whole-body metabolism, including modula-
tion of sympathetic output to adipose tissue (Wang and
He 2018) and directly modulate macrophage status in
WAT, and thermogenesis in BAT during obesity (Cer-
eijo et al. 2018; Larabee et al. 2020). Leptin, also known
as the satiety hormone, has special importance in the
context of immune system-neuronal control link in
metabolic diseases, not only because hyperleptinemia is
a hallmark of almost all metabolic diseases (Haynes et al.
1997) but also because both central and peripheral leptin
levels and leptin receptor activity alterations are associ-
ated with sympathetic nervous system disarrangement
and adipose tissue dysfunction (Ramseyer and Granne-
man 2016).
Inflammation neuronal control: the hypothalamic-
pituitary-adrenal axis and the vagal reflex
Two neuro-hormonal anti-inflammatory pathways have
been described in more detail in the literature: the
hypothalamic-pituitary-adrenal (HPA) axis and the vagal
anti-inflammatory reflex (Fig. 1) (Pavlov et al. 2003). In
reflexes involving the CNS, an environmental change ac-
tivates the afferent (sensory) neurons that signal to CNS
interneurons (integrative centers) and thus elicit a re-
sponse via efferent neural outputs (Pavlov et al. 2018).
The HPA axis induces long-lasting anti-inflammatory
responses to the whole body, but it is in general slow to
respond to immediate inflammation. By contrast, the
vagal anti-inflammatory reflex responds rapidly to in-
flammation and continuously ensures some attenuation
of pro-inflammatory cytokine production (Chavan and
Tracey 2017).
The HPA axis is activated by several stimuli including
psychological stress, which activate the paraventricular
nucleus (PVN) of the hypothalamus and leads eventually
to the release of cortisol releasing hormone (CRH) into
the anterior pituitary (Rivier and Plotsky 1986). In turn,
CRH induces the release of adrenocorticotrophic hor-
mone into the blood stream, which stimulates the pro-
duction of glucocorticoids by the adrenal cortex (Fig. 1)
(Keller-Wood and Dallman 1984). Glucocorticoids are
potent anti-inflammatory molecules whose effect is me-
diated by the glucocorticoid receptor, a nuclear receptor
expressed by almost all cells in the body and by innate
immune cells in particular (Turnbull and Rivier 1999).
While the inhibition of pro-inflammatory cytokine
production by immune cells is mediated by
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glucocorticoids when the HPA axis is activated, the vagal
anti-inflammatory reflex relies on the binding of acetyl-
choline (ACh), the main neurotransmitter used by vagus
nerve efferent fibers, and activation of nicotinic AChR
(nAChR) (Fig. 1) (Borovikova et al. 2000).
The vagal anti-inflammatory reflex, also called the
cholinergic anti-inflammatory reflex, is coordinated by
peripheral vagal afferent nerves (Tracey 2002). The CNS
activates vagal efferent nerves that synapse at the celiac
ganglion to activate parasympathetic noradrenergic in-
nervation of the spleen, leading to the release of NE
(Andersson and Tracey 2012). The NE released binds to
β2 adrenergic receptor (β2ARs) on the surface of T-cells
positive to CD4, inducing the release of non-neuronal
ACh, to thus reduce cytokine production and resolve in-
flammation through nAChR activation (Andersson and
Tracey 2012). ACh released under vagal control interacts
with α7nAChR on macrophages, an essential mediator
of vagal anti-inflammatory reflex (Fig. 1) (Wang et al.
2003). Afferent vagus nerve arrives at the brainstem of
the CNS and more specifically the NTS (Fernandez et al.
2014). The NTS, DMN (a major source of vagus nerve
efferents) and the area postrema (proximal to the cir-
cumventricular organ) form the dorsal vagal complex
(DVC), an important brainstem integrative and regula-
tory center (Berthoud and Neuhuber 2000).
Vagus activation is mediated by TNF, IL-1β, prosta-
glandins, serotonin, and other molecules released from
immune cells. For example, injection of LPS, cytokines
or other pathogens into mice and rats stimulates vagus
nerve afferent signaling, which can be traced to the NTS
and then to other brainstem and forebrain regions
(Goehler et al. 1998; Marvel et al. 2004). Electrophysio-
logical recordings of these cytokine-specific alterations
in vagus nerve activity are not obtained in genetically
modified mice in which the gene encoding TNF and IL-
1β receptors has been deleted, or in mice in which the
vagus nerve has been surgically transected (Steinberg
et al. 2016).
Anti-inflammatory reflex responses through the vagus
nerve have been described to be involved in several
pathologies. For example, Pavlov and co-workers have
described a dysfunction in ACh release mechanisms
driven by increases in cytokine production during endo-
toxemia (Pavlov et al. 2006), that was reversed by elec-
trical activation of the vagus nerve (Olofsson et al.
2015). Also, in IBD cases many groups have shown that
GI inflammation is accelerated and aggravated by vagot-
omy in mice (Ghia et al. 2007). Moreover, colonic in-
flammation was reversed by vagus nerve stimulation,
highlighting the therapeutic potential of vagus modula-
tion (Meregnani et al. 2011).
The inflammatory vagus reflex, also called inflamma-
tory axis, challenges generally held view that the
sympathetic and parasympathetic nervous systems work
in opposition, because in this instance the sympathetic
and parasympathetic nervous system work in tight col-
laboration (Rosas-Ballina et al. 2011). For example, in
myeloid cells, the anti-inflammatory pathway relies on
adrenergic and nicotinic receptors acting in parallel
(Guyot et al. 2019). By light sheet imaging of whole
clarified spleen it has been shown that there is a dense
network of catecholaminergic and cholinergic fibers
across the spleen. Moreover, electrical stimulation of the
splenic nerve was able to decrease cytokine secretion, an
effect that was abolished by both propranolol and
methyllycaconitine, but not by atropine showing that ad-
renergic receptors and α7nAChRs, but not muscarinic
AChRs were involved in the immune control by these
autonomic nerve fibers reaching the spleen (Guyot et al.
2019). The authors also found that this electrical stimu-
lation of spleen nerves alleviated the clinical symptoms
in a mouse model of RA (Guyot et al. 2019), highlighting
the importance of this approach as a therapeutic modal-
ity for patients with IMIDs.
Unilateral cervical vagotomy has been crucial to the
confirmation and discovery by Charles Serhan et al.. that
the vagus nerve contributes to the resolution of inflam-
mation (Mirakaj et al. 2014). Moreover, many studies on
the inflammatory reflex and the use of electrical stimula-
tion of the vagus nerve as a therapeutic for inflammatory
diseases has led to a resurgence of interest in bioelec-
tronic medicine (Birmingham et al. 2014). For example,
a study reported significant clinical remission in five of
seven patients with Crohn’s disease subjected to 6
months of treatment with an implanted device for vagus
nerve stimulation (Bonaz et al. 2016).
As research continues, it is likely that additional cir-
cuits, systems and mechanisms for regulating inflamma-
tion will be revealed. In this regard, in the last decade
evidence has emerged that points to the carotid body
(CB) as a new player in the immunity-nervous system
link and electrical modulation of the carotid sinus nerve
(CSN) as a possible way to decrease systemic inflamma-
tion (Santos-Almeida et al. 2017).
The carotid body: a new intervenient in the
neuroinflammation control
Hermann and co-workers were the first to suggest that
the systemic endotoxin response was not dependent on
the vagus alone (Hermann et al. 2001). The authors de-
scribed that LPS activation of DVC neurons was not af-
fected by bilateral vagotomy and suggested that the NTS
could be a primary central nervous system detector of
cytokines, or another neural afferent pathway distinct
from vagus nerves (Hermann et al. 2001).
Supporting the involvement of other afferent signals,
we discuss in the next sub-section some studies showing
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the involvement of CB and CSN activity on the effects of
inflammatory mediators, promoted by LPS, lysophospha-
tidic acid (LPA) or Ovalbumin (OVA).
CB responses to inflammatory mediators
The CB is the largest paraganglion and the most vascu-
larized organ in the body (Mascorro and Yates 1980), lo-
cated in the region where the common carotid artery
bifurcates to form the internal and external carotid ar-
teries. This bilateral organ is a polymodal sensor, capable
of detecting alterations in oxygen and carbon dioxide
concentrations, as well as diverse mediators such as
angiotensin II, leptin or insulin (Conde et al. 2014;
Kumar and Prabhakar 2012). It comprises integrated
units of chemoreceptor neural cells, glial cells, and vas-
cular cells surrounded by connective tissue, which col-
lectively constitute a highly adaptive chemosensory
organ (Liu et al. 2009) innervated by the CSN (Verna
1997). Afferent CSN fiber inputs are integrated in the
NTS, in a similar manner to vagal afferents (Fig. 1) (Fin-
ley and Katz 1992). The CB is a conglomeration of the
type I (glomus) chemoreceptor cells, and type II (susten-
tacular) cells that are similar to glia. Type I cells are the
most abundant cell type within the CB, with a minimum
of 3 and up to a maximum of 8 for each type II cell in
most of the species (De Kock and Dunn 1966; Verna
1979).
Infiltrations of macrophages into the CB have long
been noticed, but the reason(s) for their presence has
been overlooked for many years (Kumar and Prabhakar
2012). However, in recent years accumulating evidence
suggests that the CB has an immunomodulatory func-
tion, in communicating peripheral immune status to the
brain (Wang et al. 2002; Wang et al. 2006). It is also evi-
dent that the CBs exhibit histological features of acute
inflammation, that in turn alter its function under condi-
tions that mimic disease states such as sepsis and endo-
toxemia (Fernández et al. 2008). Reyes et al. found that
bilateral carotid/sinus chemo-denervation after intraperi-
toneal administration of LPS suppressed both the LPS-
induced increase in the number of c-Fos+ neurons
within the NTS and the increased levels of plasma corti-
sol, suggesting that the CB performs a neuroimmuno-
modulatory function (Reyes et al. 2012).
Moreover, systemic inflammatory responses, like the
one induced by pathogen-associated molecular pattern
molecules (PAMPs), such as LPS endotoxin, increased
tonic CB chemosensory activity and reduced its respon-
siveness to transient excitatory or depressant stimuli.
These effects were also prevented by prior bilateral ca-
rotid neurotomy (Fernández et al. 2008). Furthermore,
LPS-induced sepsis in rats submitted to carotid chemo/
baro-denervation showed a blunted tachypneic response
and enhanced tachycardia and hypotension as well as
enhanced epinephrine and TNF-α responses, and earlier
multiple organ dysfunction onset with a lower survival
time compared with sham operated-LPS rats (Nardocci
et al. 2015). Also, hyperoxia-induced reduction of CB
chemosensory activity in animal models of sepsis was as-
sociated with higher plasma levels of pro-inflammatory
cytokines and mortality in septic rats (Rodríguez-Gonzá-
lez et al. 2014). More recently, Santos-Almeida et al.
showed that CSN electrical stimulation in conscious rats,
modulates the innate immune response to LPS by at-
tenuating the plasma levels of TNFα, IL-1β and IL-6 as
well as by increasing the anti-inflammatory cytokine IL-
10 (Santos-Almeida et al. 2017), and that this chemore-
flex anti-inflammatory pathway was decreased by bilat-
eral carotid chemoreceptor denervation and by the use
of propranolol and methylatropine, blockers of sympa-
thetic and parasympathetic pathways, respectively (Fig.
1) (Santos-Almeida et al. 2017). Additionally, LPA, an
important mediator in allergen-induced asthmatic lung
inflammation (Knowlden and Georas 2014) induced CB
activation in a rat model of asthma (OVA-sensitized), an
effect mediated by TRPV1 and LPA-specific receptors in
the CB and that in turn activated parasympathetic
(vagal) reflexes that led to acute bronchoconstriction
(Jendzjowsky et al. 2018). All in all, these findings
strongly support by hold the view that the CB supports
an immune-CNS axis.
Therefore, a role in the response to some acute and
chronic pathophysiological reactions to high levels of in-
flammatory and immune mediators in the bloodstream
may originate from changes in CB function, its integra-
tion at the CNS level and/or in the control of sympa-
thetic and parasympathetic efferents (Fig. 2).
Presence and effects of inflammatory cytokines in CB and
its outputs
TNF-α receptor expression in human, rat and mouse
CBs was observed using microarray analysis (Mkrtchian
et al. 2012) and western blot (Sacramento et al. 2020).
Also, Fernandez et al. showed that the canonical LPS re-
ceptor TLR-4, and TNF-α receptors are functional (Fer-
nández et al. 2008; Fernández et al. 2011). This cytokine
and cytokine receptor expression on CB was not re-
stricted to immune cells that infiltrated on this organ. In
cats, in vitro recordings of the CSN activity showed that
TNF-α administration did not modify basal CSN chemo-
sensory activity but reduced in a dose-dependent man-
ner the increase in the frequency of chemosensory
discharge induced by hypoxia (Fernández et al. 2008). By
contrast, in rats, TNF-α administration in dissociated
type I cells increased [Ca2+]i in response to acute hyp-
oxia, an effect that was greater in cells obtained from the
CB of rats exposed to chronic intermittent hypoxia (Lam
et al. 2012) and chronic hypoxia (Lam et al. 2008).
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Additionally, TNF-α intravenous systemic administration
in a dose of 5 ng/ml in the rat induced an increase in basal
ventilation. This effect was abolished by CSN resection,
demonstrating that TNF-α-induced increase in ventilation
is mediated by the CB (Sacramento et al. 2020).
Glomus cells in the CB also displayed strong IL-1R
(Wang et al. 2002) and IL-6Rα (Wang et al. 2006) im-
munoreactivity, and cultured rat CB type I cells
responded to IL-6 administration. Therefore, there are
specific receptor binding sites for cytokines on the CB
type I cells, that support immune system-to-brain inter-
actions (Fan et al. 2009). Also, studies of cultured type I
cells harvested following 1 day of in vivo hypoxia showed
elevated transcript levels of inflammatory cytokines and
in situ hybridization studies confirmed expression of IL-
6 in type I cells and also showed that chronic hypoxia
induces IL-6 expression in supporting type II cells (Liu
et al. 2009).
Additionally, IL-1β administration significantly increases
CSN chemosensory discharge in anesthetized rats, an ef-
fect that was abolished by the administration of an IL-1β
receptor antagonist (Shu et al. 2007). However, while IL-
1β application did not modify the release of catechol-
amines from the rat CB, extracellular administration of
IL-6 induced a rise in [Ca2+]i and catecholamine release
from in vitro-cultured CB type I cells (Fan et al. 2009). As
described for TNF-α, the administration of IL-6 in the rat
femoral vein in doses of 0.5 and 5 ng/ml augmented mi-
nute ventilation, an effect that was prevented by CSN de-
nervation, suggesting that the effect of IL-6 on ventilation
is CB-mediated (Sacramento et al. 2020).
Confirming that the CB participates in immune-brain
signaling in humans, CBs from male volunteers exposed
to hypoxia (10% O2) during a 1 h exhibit an increase in
the IL-1β, IL-6, IL-8 and IL-10, whereas the release of
IL-2, IL-5 and TNF-α could not be detected (Kåhlin
Fig. 2 Postulated link between diet-induced dysmetabolism and the brain-carotid body axis: Hypercaloric diets generate a dysmetabolic state
characterized by hyperleptinemia, hyperinsulinemia and inflammation, transduced by an overexpression of inflammatory cytokines. These key
mediators contribute to carotid body (CB) dysfunction that is in the genesis of metabolic diseases since all these mediators are able to activate
the CB, by acting on respective receptors within the organ, and modulate its function, e.g. via the release of neurotransmitters. Carotid sinus
nerve (CSN) transmit this information from CB to the central nervous system, namely to the nucleus tractus solitarii (NTS), leading to the
activation of both sympathetic and parasympathetic nervous systems to the efferent organs to modulate metabolism. Also, CSN information
integrated in the NTS will impair satiety control and food intake, aggravating hyperphagia. All together, these afferent stimuli (metabolic vs
inflammation) and intensity of reflexes stimulation may contribute to the activation or to different degrees of activation of different pathways
contributing to dysmetabolic states
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et al. 2014). The same authors also showed that recep-
tors for IL-1, IL-6 and IL-10 co-localize in human CB
type 1 cells (Kåhlin et al. 2014).
Apart from relaying circulating immune signals to the
brain in response to acute/intermediate systemic inflam-
matory conditions, the effect of proinflammatory cyto-
kines on the CB has been proposed to be in the basis of
CB overactivation that is associated with several diseases,
such as obstructive sleep apnea and obesity that are as-
sociated with chronic systemic inflammation (Conde
et al. 2017; Oyarce and Iturriaga 2018; Sacramento et al.
2020). Additionally, the role of CB on inflammation
regulation blends with the autonomic reflex since CB
stimulation provokes a wide array of cardiopulmonary
and autonomic reflexes, as well as endocrine responses
(e.g., plasma release of catecholamines and cortisol)
(Fitzgerald 2014). Moreover, it is well described that dis-
eases that are associated with high autonomic activity
are associated with increased CB dysfunction (Paton
et al. 2013), highlighting the link between inflammation
– CB – autonomic reflex. For example, proinflammatory
cytokines have been proposed as mediators of the che-
mosensory potentiation induced by chronic intermittent
hypoxia (CIH), a condition that mimics obstructive sleep
apnea (Del Rio et al. 2011; Iturriaga et al. 2009; Lam
et al. 2012). Del Rio et al. found that ibuprofen, an anti-
inflammatory drug, prevented the CIH-induced overex-
pression of cytokines in the CB and hypertension, but
failed to block the enhanced CB chemosensory re-
sponses to acute hypoxia in Sprague-Dawley rats sub-
mitted to 21 days of intermittent hypoxia. These results
show that proinflammatory cytokine levels may contrib-
ute to CIH-induced hypertension, highlighting another
level of immunomodulation through the CB chemoreflex
pathway (Del Rio et al. 2012). Another type of chronic
hypoxia that also runs with chronic inflammation is
chronic sustained hypoxia (Eltzschig and Carmeliet
2011). Chronic sustained hypoxia leads to profound
morphological, biochemical and functional changes in
the CB (Barnard et al. 1987; Bisgard 1994; Bisgard 1995;
Bisgard 2000; Powell 2007; Powell et al. 2000) and is as-
sociated with the upregulation of the expression and
function of proinflammatory cytokines in the rat CB
(Lam et al. 2008). The expression of IL-1r1, gp130 and
TNFr1 receptors was increased in the rat CB at 3, 7 and
28 days of chronic hypoxia, as were the gene transcripts
of inflammatory mediators, inducible nitric oxide syn-
thase and chemokines (MCP-1, CCR2, MIP-1alpha, and
ICAM-1). Additionally, application of exogenous cyto-
kines increased [Ca2+]i responses to acute hypoxia in the
dissociated fura-2-loaded glomus cells, a response that
was significantly higher than in the normoxic group
(Lam et al. 2008). Confirming that proinflammatory cy-
tokines drive CB alterations that contribute to diseases
associated with chronic systemic inflammation, common
anti-inflammatory drugs (e.g. ibuprofen and dexametha-
sone) also reduced macrophage invasion, cytokine ex-
pression, and blocked the augmented CSN discharge
induced by chronic hypoxia (Kumar and Prabhakar
2012; Liu et al. 2009). In addition to the above, pro-
inflammatory cytokines and the transcripts of many
anti-inflammatory cytokines (e.g. nuclear factor (NF)-κB,
IL-10R and HMGB-1) have also been found in human
and mouse CBs (Mkrtchian et al. 2012). It was also
shown in human CBs that prolonged hypoxia releases
not only pro-inflammatory cytokines but also anti-
inflammatory cytokines, and that the corresponding
cytokine receptors are expressed in the type I cells. In
short, human CBs incorporate key components required
to support immune system signaling (Kåhlin et al. 2014).
Apart from PAMPs, such as LPS, it was recently de-
scribed that the CBs may also be activated by endogen-
ous damage-associated molecular patterns, inflammatory
mediators of aseptic tissue injury that are recognized by
the same pathogen recognition receptors as PAMPs, in-
cluding HMGB1 (all-thiol and disulfide forms) and S100
A8/A9 (MKrtchian et al. 2020). It was found that
HMGB1, S100 A8/A9 and blood plasma from rats sub-
jected to tibia surgery, a model of aseptic injury, induce
the release of ATP and dopamine - key CB neurotrans-
mitters – as well as TNF-α from ex vivo rat CBs
(MKrtchian et al. 2020). Moreover, all-thiol HMGB1 and
its reduced form, modulate several immune response
genes including important pro-inflammatory cytokines,
such as IL-1α and IL-1β (MKrtchian et al. 2020).
Recently our group have reviewed the key mediators
that link CB dysregulation with the pathogenesis of
metabolic diseases. We have demonstrated that these
pro-inflammatory cytokines and also insulin and leptin
are able to activate the CB and modulate its function.
So, hyperinsulinemia, hyperleptinemia, and high pro-
inflammatory cytokine levels seem to be determining
factors that contribute to the CB overactivation in meta-
bolic diseases (Fig. 2) (Sacramento et al. 2020).
Altogether these data support the view that CB func-
tion is regulated by endogenous mediators of innate im-
munity, and confirms once more that the CB is a key
organ linking the immune system to the brain.
The inflammatory reflex—linking immunity and
metabolism
The vagus nerve, specially the efferent arm of the vagus
nerve system, is a major constituent of the inflammatory
reflex, or the efferent vagal anti-inflammatory reflex. In
addition to its role in the regulation of metabolic
homeostasis, the vagus is also crucial for the close rela-
tionship between the immune response and parasympa-
thetic regulation of metabolism (Tracey 2002). This arm
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of immunity regulation is relayed by efferent nerves, that
carry and array of brain outputs that modulate the in-
nate immune system across the body (Fig. 1).
Inflammation is normally a temporary event that has to be
resolved with achieving immune and physiological homeo-
stasis. This anti-inflammatory reflex acts on the inflamma-
tion resolution by promoting anti-inflammatory molecules
release like IL-10, TGF-beta and soluble cytokine receptors
to stop proinflammatory progression (Pavlov and Tracey
2012a). Disruption of the vagal anti-inflammatory reflex ac-
tion results in continual proinflammatory cytokines produc-
tion and activity, and chronic inflammation, which
contribute to the pathogenesis of inflammatory and meta-
bolic diseases (Donath and Shoelson 2011; Hotamisligil
2017). It is well known that in situations of obesity, vagus
nerve activity is decreased and interventions to activate cho-
linergic pathways in the vagus efferent arm of the inflamma-
tory reflex have been shown to suppress obesity-associated
inflammation and concomitant reversal of metabolic alter-
ations (Carnethon et al. 2003; Marrero et al. 2010; Wang
et al. 2011).
In the scenario of resolution of inflammation by the modu-
lation of efferent vagus nerves within peripheral tissues, the
α7nACh receptor is extremely important. The use of agonists
of this receptor being identified as useful anti-inflammatory
therapeutics (Pavlov et al. 2007; Wang et al. 2011). The work
of Wang et al. (Wang et al. 2011) revealed that activation of
this pathway by nicotine in obese animal models significantly
improved insulin sensitivity and glucose homeostasis, and
suppressed adipose tissue inflammation. Moreover, these
beneficial effects were abolished in α7nAChR KO mice and
pro-inflammatory cytokines expression was increased in this
KO mice model (Wang et al. 2011).
The mechanoreceptors and chemoreceptors present in
the afferent vagus nerves contribute to metabolic regula-
tion by detecting changes in nutrients and metabolic mol-
ecules in the gastrointestinal tract, adipose tissue and the
liver, such as glucose, lipids, insulin, leptin and other mol-
ecules, and relay information on their respective levels to
the brain. Efferent vagus nerves, on the other hand, trans-
mit the brain-derived outputs to the gastrointestinal tract,
liver, pancreas and other tissues (Yi et al. 2010). For ex-
ample, post-prandial state endotoxemia and inflammation
have been proposed to be modulated by vagus nerve and
inflammatory reflex. Intriguingly, TLR4 expression in the
afferent vagus nerves after a meal provides a molecular
sensory component that facilitates signalling to the brain
in order to promote post-prandial inflammation reso-
lution (de Lartigue et al. 2011; Pavlov and Tracey 2012b).
Inflammatory reflex role on metabolism-related hormone
activity
Cholecystokinin (CCK), is a hormone secreted by the
enteroendocrine cells in the duodenum which stimulates
the digestion of fat and proteins, which also acts on
CCK1 receptors to inhibit gastric function, food intake
and satiation in response to intestinal nutrients in
humans (Little et al. 2005; Moran and Kinzig 2004).
These effects are mainly mediated by the activation of
the vagal afferents (Luyer et al. 2005) and probably mod-
ulated by the neuro-immune pathway. In fact, after a
dietary lipid infusion, CCK acts both via vagus nerve af-
ferents and directly in the brain to trigger efferent vagus
nerve signaling, which in turn suppresses the release of
proinflammatory cytokines and stops postprandial in-
flammation (Luyer et al. 2005). Ghrelin is another hor-
mone secreted not only in the gastrointestinal tract but
also in the pituitary, hypothalamus and pancreas among
other organs, which plays a role in lipid metabolism, glu-
cose homeostasis, growth hormone release, appetite
stimulation, body weight gain, and adiposity whose
mechanism of action seems to include its action on the
anti-inflammatory vagal pathway (Ronveaux et al. 2015).
The effects of ghrelin are mediated by central and per-
ipheral mechanisms, its pre-eminent action being the ac-
tivation of its receptors in the hypothalamus and
activation of vagal afferents (Ronveaux et al. 2015). Elec-
trophysiological studies reveal that, by contrast to CCK,
ghrelin attenuates vagal activity. Therefore, these two
hormones provide counterregulatory inputs to mecha-
nisms that control metabolism, food intake and immun-
ity (Date et al. 2002). Ghrelin, the release of which is
stimulated by ACh, has known anti-inflammatory effects.
Intravenous ghrelin administration in septic mice de-
creases the levels of the pro-inflammatory cytokines IL-1
and IL-6, and ghrelin contributes to the regulation of
and its release is regulated by the vagus, in a manner
partly coordinated by ghrelin receptors expressed in the
DMN of the vagus, (Wu et al. 2007; Zhang et al. 2004).
Insulin and leptin are other hormones deeply involved
in metabolic control (Date et al. 2002). Leptin acts on
nodose ganglion of the vagus nerve increasing electro-
physiological activity of vagal afferent nerves that con-
tribute to energy homeostasis. Leptin resistance of vagal
afferents leads to hyperphagia and an obesity phenotype
(Ronveaux et al. 2015). By contrast to ghrelin action, lep-
tin potentiates CCK function on food consumption and
metabolism control (de Lartigue 2016). In obesity, the
action of these appetite and metabolism-controlling hor-
mones is impaired since LPS production in the gut is in-
creased (DiBaise et al. 2008). LPS upregulates the
expression of suppressor of cytokine signaling-3 that
elicits leptin resistance through TLR4 expressed in the
vagal afferent pathway (de Lartigue et al. 2011). Such
leptin resistance occurs at the vagus nerve before it oc-
curs at the hypothalamus in an obese animal model (de
Lartigue et al. 2011). (Ueno and Nakazato 2016) have
shown that mice fed with a high-fat diet develop
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inflammation in the intestinal tract as a result of
changes in the intestinal flora, and that this inflam-
mation spreads to the vagus nerve ganglion cells and
the hypothalamus through the vagal afferent pathway
distributed along the intestinal tract, leading to dis-
rupted transmission of signals for appetite regulation
(Naznin et al. 2015).
In addition to the above, insulin action and secretion
is connected to changes in vagal neuron transmission to
and receipt of information from the brain (Meyers et al.
2016). Nodose ganglion neurons of vagal afferents ori-
ginating from the endocrine pancreas are activated by
insulin and may inform about pancreatic insulin levels
to the brain (Iwasaki et al. 2013). These fibers project to
the NTS from where inputs are relayed to hypothalamic
areas, such as the arcuate nucleus (ARC) and PVN,
which are involved in the regulation of food intake and
autonomic nervous system activity (Morton et al. 2006).
Hepatic glucose metabolism is also regulated by vagal
control of insulin action at this tissue, as revealed by
studies on the effects of intracerebroventricular (ICV)
insulin administration, the action of which was abolished
by hepatic vagotomy (Pocai et al. 2005a; Pocai et al.
2005b). Hepatic inflammation is also regulated by cen-
tral insulin action on efferent output through hepatic
branches of vagal nerves, in part due to the fact that IL-
6 is expressed in hepatic resident macrophages, Kupffer
cells (Inoue et al. 2006).
Therefore, the activation of inflammatory pathways
other than the vagus nerve interferes with insulin and
leptin signaling in the brain and also in peripheral tis-
sues, contributing to insulin resistance in obesity and
metabolic disorders, such as type 2 diabetes.
Inflammatory reflex in obesity
In obesity, chronic adipose tissue inflammation, sympa-
thetic nerves and immune cells show an interconnection
in the development of associated comorbidities. It is
known that sympathetic nerves release NE in adipocytes
promoting lipolysis and/or thermogenesis (Larabee et al.
2020). Advanced imaging techniques combined with
optogenetics and pharmacologic approaches have
allowed the visualization of the innervation of adipose
tissue by the sympathetic nervous system and the con-
firmation that sympathetic innervation is necessary and
sufficient to promote lipolysis in WAT (Zeng et al.
2015). Sympathetic innervation originates in five distinct
brain regions, including the PVN, where leptin-mediated
pro-opiomelanocortin (POMC) and agouti-related pro-
tein (AgRP) pathways converge. Adipose tissue homeo-
stasis has also been described to be controlled by a
neuroendocrine loop with leptin in the center of the or-
chestra acting on neural circuits in the hypothalamus
and other regions in the brain to regulate food intake
and peripheral metabolism (Friedman and Halaas 1998).
Experimental leptin levels modify sympathetic output to
adipocytes, leading to alterations in thermogenesis in
BAT and lipolysis and/or browning in WAT (Shen et al.
2007). Central administration of leptin increases sympa-
thetic activity on WAT promoting lipolysis, an effect
prevented by the administration of the β-blocker pro-
pranolol, suggesting that leptin effects on WAT are me-
diated by NE binding to β-adrenergic receptors within
adipose tissue (Shen et al. 2007). Therefore, circulating
leptin levels have been shown to be proportional to adi-
pose tissue size and function, and thus help maintain
adiposity within a very narrow physiological range (Phil-
lips et al. 2000). Despite our growing knowledge of the
precise neural circuitry responsible for the control of
sympathetic nervous system output, the specific mecha-
nisms involved in the activation of leptin receptor-
expressing neurons remains unclear, as is the path to
peripheral and central leptin resistance (Haynes et al.
1997; Mahú and Domingos 2017).
Immune cells in adipose tissue also participate in the
pathophysiology of obesity, with macrophages being key
contributors in this context. Macrophage polarization is
particularly relevant, as classically (M1-like) and alterna-
tively (M2-like) activated macrophages are characteristic
of obese and lean adipose tissue phenotypes (Wu et al.
2011). The hyperlipidemia characteristic of obesity inun-
dates TLR4 in adipose tissue macrophages, which leads
to an M1-like phenotype that includes release of pro-
inflammatory cytokines, such as TNF and IL-6 (Osborn
and Olefsky 2012; Shi et al. 2006). This stimulation of
pro-inflammatory factors will aggravate insulin resist-
ance and glucose intolerance linked with obesity due to
the dysfunction of insulin signaling cascade activation
and glucose transporter recruitment to the membrane
(Osborn and Olefsky 2012). Recently, Pirzgalska et al.
showed that adipose tissue macrophages are specific
macrophages, called sympathetic neuron-associated
macrophages (SAMs) that express neural- and
adrenergic-related genes different from other macro-
phages and that produce NE following sympathetic acti-
vation (Pirzgalska et al. 2017). Also, they showed, in high
fat diet obese mice, that these adipose tissue specific
macrophages are augmented in obesity and promoted an
increased clearance of NE (Pirzgalska et al. 2017), and
that they are in higher number in visceral WAT than in
subcutaneous adipose tissue or other fat pads (Mahú
and Domingos 2017). Altogether these results suggest
that these adipose tissue SAMs are the link between im-
mune system and sympathetic activation in the modula-
tion of adipose tissue in both physiologic and obesity
conditions and confirm the visceral fat pad as being of
huge importance for the maintenance of immune bal-
ance and metabolism.
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Some studies have shown that gut and hepatic metab-
olism regulation are also modulated through the activa-
tion of vagal afferent pathways that innervate these
tissues, and that they are also impaired in rodent models
of type 2 diabetes (Lee et al. 2012). In fact, liver appears
as a crucial target tissue for brain-immune axis control
of metabolism. As already mentioned, central insulin ac-
tion suppresses hepatic glucose production by downreg-
ulating the gene expression of gluconeogenic enzymes
such as G6pc which encodes for glucose-6-phosphate
(Kimura et al. 2016; Obici et al. 2002). In fact, the sup-
pression of hepatic glucose production using the
hyperinsulinemic-euglycemic clamp technique is abol-
ished by insulin receptor deficiency, insulin receptor
knockdown, and PI3-K inhibition in the hypothalamus
(Inoue et al. 2006; Obici et al. 2002). Also, electrical
stimulation of the vagus nerve has been shown to sup-
press the induction of inflammatory cytokine expression
including IL-6 in the liver following LPS administration
(Borovikova et al. 2000). This shows the role of hepatic
vagal branches in the regulation of Kupffer cell action over
the central insulin-mediated hepatic responses of IL-6/
STAT3 signal and regulation of gluconeogenic enzyme
gene expression (Kimura et al. 2016). Importantly, this
regulatory mechanism is impaired in metabolic diseases
such as obesity and type 2 diabetes (Taylor 1999). Addition-
ally, catecholamine excess seems to be involved in hepatic
glucose overproduction characteristic of obesity and other
metabolic disorders, which suppress the induction of gluco-
neogenic enzymes (Nguyen et al. 2019). Moreover carve-
dilol, a third-generation beta-blocker and α1 adrenoceptor
antagonist, blunted these hepatic dysfunctions in an animal
model of high fat diet-induced obesity (Feuerstein and Ruf-
folo Jr 1995; Stoschitzky et al. 2001).
In conclusion, attenuation of vagus nerve signaling
and consequently the anti-inflammatory reflex aggra-
vates not only obesity and obesity-related metabolic dis-
orders, but also the disarrangement of the sympathetic-
immune link. Therefore, dysmetabolism and inflamma-
tory pathway activation leads to a vicious cycle that ac-
celerates many metabolic and inflammatory disorders
(Pavlov and Tracey 2012a).
The carotid body as a new player in the link
between immunity and dysmetabolism
In recent years, CB overactivation has been associated
with several cardiometabolic diseases, such as type 2 dia-
betes, essential hypertension and hypertension associated
with obstructive sleep apnea (Conde et al. 2017; Fletcher
et al. 1992; Narkiewicz et al. 1999; Ribeiro et al. 2013).
These pathologies share an increase in sympathetic tone
that is linked with CB and CSN hyperactivity, both of
which contribute to pathogenesis (Conde et al. 2018;
Dos Santos et al. 2018; Iturriaga 2018; Paton et al. 2013).
In 2013, Ribeiro et al. (Ribeiro et al. 2013) described
for the first time that the CB is a peripheral regulator of
insulin sensitivity and thus in the genesis of metabolic
diseases, since bilateral CSN resection prevented the de-
velopment of dysmetabolic changes induced by hyperca-
loric diets (Ribeiro et al. 2013). After that pioneering
study, the same authors found that CSN resection nor-
malized systemic sympathetic nervous system activity,
insulin sensitivity and glucose tolerance and reversed
weight gain induced by high-energy diets in prediabetes
and early type 2 diabetes animals models (Sacramento
et al. 2017), and in models of obesity (Melo et al. 2019)
by improving glucose uptake by the liver and perienteric
adipose tissue (Sacramento et al. 2017). In agreement
with the hypothesis that CB overactivation promotes
metabolic deregulation via an increase in sympathetic
nervous system activity (Conde et al. 2017; Conde et al.
2014), the authors found that animal models of meta-
bolic dysfunction induced by hypercaloric diets exhibit
an overactivation of CB, by identifying associated in-
creases in basal ventilation, ventilatory responses to is-
chemic hypoxia and CB chemoreceptor cell activity, as
well as by the enlargement of the CB (Fig. 2) (Dos San-
tos et al. 2018; Ribeiro et al. 2013). CB dysfunction in
metabolic disease states was consistent with the in-
creased activity of the CSN electrophysiological record-
ings both in vivo (Cracchiolo et al. 2019b) and ex vivo
(Conde et al. 2018) in the rat. Demonstrating that these
mechanisms are also present in humans, Cramer et al.
(Cramer et al. 2014) showed that patients with type 2 dia-
betes exhibit CBs 20–25% larger than control volunteers
and more recently it was described that prediabetes patients
exhibit increased CB activity (Cunha-Guimaraes et al.
2020), measured by the double-breath Dejours test, that
evaluates CB chemosensitivity in patients while breathing 2
breaths of 100%O2 (Dejours 1962; Dejours 1963).
The important role of CB in both physiologic and
pathological conditions is additionally supported by its
metabolic sensing properties that have been highlighted in
the last decades and that give the CB the capacity to re-
spond to changes in circulating metabolic mediators, such
as insulin and leptin (Fig. 2) (Prabhakhar and Joyner
2014). The emerging information on the role of CB as a
metabolic sensor stands, naturally, on their anatomic loca-
tion and crucial role as an alarm mechanism to the central
nervous system in acute emergency situations that may
lead to neuroglycopenia (Conde et al. 2018), as well as in
chronic situations requiring maintenance of the balance
between physiology and pathological resolution.
Insulin role in CB activity
Insulin and leptin are potent sympathetic activators
(Marino et al. 2011) whose activity in the brain have
been highlighted as one of the major determinants of
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peripheral glucose and insulin responsiveness and lipid
metabolism (Kimura et al. 2016). However, some old
and recent evidences indicated that both these hormones
might work outside the brain to activate autonomic ef-
ferent nerves. More than 50 years ago, Pereda et al. (Per-
eda et al. 1962) observed that insulin administration into
the carotid artery of anesthetized dogs induced a higher
increase in sympathetic activity than the systemic ad-
ministration of insulin, suggesting a role for the periph-
eral nervous system in insulin-mediated increase in
sympathetic nervous system activity. Some of the first
evidences that insulin is capable of stimulating CB che-
moreceptors came from studies dedicated to evaluate
the CB glucose sensing properties and in where
hypoglycemia was achieved through insulin administra-
tion (Bin-Jaliah et al. 2004; Ward et al. 2007). The effect
of insulin per se on ventilation and on CB activity was
later confirmed by Ribeiro et al. (Ribeiro et al. 2013) in
anaesthetized rats, since insulin increased ventilation in
a dose-dependent manner during an euglycemic clamp,
an effect that it was absent in animals submitted to the
CSN resection. Additionally, the authors demonstrated
the existence of insulin receptors at the CB and its phos-
phorylation in response to insulin and that insulin, in
physiological concentrations, is able to elicit a neurose-
cretory response from the CB, measured as the increase
in [Ca2+]i and the release of ATP and dopamine from
the CB (Ribeiro et al. 2013). Insulin administered in vivo
in the rat was also capable to increase CSN and sympa-
thetic nervous system electrophysiological activities. This
effect of insulin on sympathetic activity was prevented
by CSN bilateral denervation (Cracchiolo et al. 2019a),
meaning that the effect of insulin on the overall-
sympathetic nervous system activity is mediated by the
CB. The effects of insulin on ventilation were recently
confirmed in humans. Minute ventilation increase dur-
ing an hyperinsulinemic-euglycemic clamp and elevated
plasma insulin levels increases minute ventilation inde-
pendently of alterations in glucose levels (Barbosa et al.
2018), confirming the role of insulin as a contributor to
CB dysfunction in metabolic diseases. Recently, it was
described that CB increased activity is associated with
increased circulating insulin levels and insulin resistance
evaluated by HOMA-IR (Fig. 2) (Cunha-Guimaraes et al.
2020).
Involvement of leptin signaling in CB activity
Leptin is another hormone that has been shown to acti-
vate the CB. Leptin may thus contribute to CB dysfunc-
tion and increased sympathetic activity seen is obesity
and obesity-related syndromes, as OSA and metabolic
syndrome (Fig. 2) (see e.g. (Kim and Polotsky 2020; Sac-
ramento et al. 2020)). Leptin receptors are present in
type I cells of mice, rat and human CBs (Caballero-Eraso
et al. 2019; Messenger et al. 2012; Porzionato et al. 2011;
Ribeiro et al. 2018). Within human CBs approximately
40% of type I cells were immunoreactive to leptin, with
57% of the type I cells immunoreactive to all leptin re-
ceptors isoforms, and approximately 30% immunoreac-
tive for Ob-Rb isoforms (Porzionato et al. 2011). Acute
exogenously applied leptin increased basal spontaneous
ventilation as well as ventilatory responses to ischemic
and hypoxic hypoxia in mice and rats, these effects of
which were abolished or attenuated by CSN denervation
(Caballero-Eraso et al. 2019; Olea et al. 2015; Ribeiro
et al. 2018; Sacramento et al. 2020). In agreement with
these excitatory effects of leptin on breathing mediated
by the CB, exogenous leptin was also able to increase
electrophysiological CSN activity measured ex vivo and
in vivo (Caballero-Eraso et al. 2019; Ribeiro et al. 2018;
Shirahata et al. 2015). CBs of insulin resistant rats sub-
mitted to a high-fat diet (60% energy from fat) for 3
weeks exhibited a higher degree of CB activation (in-
creased expression of tyrosine hydroxylase, release of
neurotransmitters and ventilation) with similar levels of
hyperinsulinemia when compared with animals submit-
ted to a high sucrose diet (Ribeiro et al. 2013). This led
Conde et al. to hypothesize that a factor related to obes-
ity could contribute to CB overactivation in metabolic
diseases.
The effects of leptin on satiety (Dalamaga et al. 2013)
are opposite to the acute and chronic effects of leptin
mediated by the CB. Exogenous administration of leptin
during 7 days did not modify basal ventilation but in-
creased the hypoxic ventilatory response in rats (Yuan
et al. 2018). In agreement with the lack of effects of lep-
tin on baseline due to a higher tonic activity of the
organ, rats submitted to a high-fat diet for 3 weeks ex-
hibited increased basal ventilation (Ribeiro et al. 2018;
Ribeiro et al. 2013) but showed decreased excitatory ef-
fects of leptin in spontaneous ventilation (Ribeiro et al.
2018; Sacramento et al. 2020), effects that were not
modified with CSN resection (Sacramento et al. 2020).
Also, leptin in these high fat rats was unable to increase
electrophysiological sympathetic nervous system activity,
measured at the cervical sympathetic chain, or the basal
CSN electrophysiological activity (Ribeiro et al. 2018;
Sacramento et al. 2020). Moreover, it was shown that in
low-grade obese prediabetic animals the expression of
leptin receptors was increased (Ribeiro et al. 2018) sug-
gesting a feed-forward mechanism to promote CB acti-
vation during hyperleptinemic states. Altogether these
results lead Conde et al. to postulate that leptin could be
involved in the development of CB dysfunction in initial
states of dysmetabolism that run with high leptin levels
but before chronic hyperleptinemia is established (Fig. 2)
(Ribeiro et al. 2018; Sacramento et al. 2020). In agree-
ment with the development of a CB-leptin resistant
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state, rats exposed to hypercaloric diets during longer
periods of time (8 weeks (Yuan et al. 2018), 16 weeks
(Rakoczy et al. 2018) or 25 weeks (Sacramento et al.
2018)) show decreased spontaneous basal ventilation
and decreased hypoxic ventilatory responses. These out-
comes are similar to those observed with the obese
Zucker rat, a model that lacks the gene coding for the
Ob-R leptin receptor (Yuan et al. 2018).
Taking into account the close connection between in-
sulin resistance, leptin resistance and dysmetabolism
with chronic low-grade inflammation it becomes im-
perative to understand the mechanisms under the basis
of this connection and the role of peripheral nervous
system in this scenario. In fact, in an animal model of
prediabetes, that combined insulin resistance, obesity
and hypertension, obtained by submitting rats to a lipid-
rich diet (60% energy from fat) for 3 weeks an increase
in the IL-1 receptor in the CB was observed (Sacramento
et al. 2020). Consistent with this increased inflammatory
pattern, preliminary results showed that the expression
of the receptor TNF-R1 in the CB increased in this ani-
mal model, although with no alterations on IL-6Rα re-
ceptor levels promoted by the high-fat diet. When the
expression of the receptor for IL-1β, IL-6 and TNF-α in
the CB was evaluated in a rat model of an early phase of
type 2 diabetes, obtained by submitting the animals to a
lipid rich diet combined with sucrose in the drinking
water for 25 weeks, the expression of TNF-R1 receptor
was increased, with no changes the expression of IL-6Rα
and IL-1R. Altogether these results suggest that alter-
ations in IL-1β and TNF-α signaling, and in the CB in-
flammatory sensing and reflex mechanisms might
contribute to the increase in the CB activity and the al-
tered link immunity-metabolism-nervous system ob-
served in metabolic diseases (Fig. 2) (Cracchiolo et al.
2019a; Cracchiolo et al. 2019b; Cunha-Guimaraes et al.
2020; Ribeiro et al. 2018; Ribeiro et al. 2013). Knowing
that the CB/CSN activate and interfere with both sympa-
thetic (Fletcher et al. 1992; Marshall 1994; Sacramento
et al. 2017; Zera et al. 2019) and parasympathetic ner-
vous (Jendzjowsky et al. 2018) systems we can postulate
that different stimuli (metabolic vs inflammatory) and
intensity of stimulation may contribute to the activation
or to different degrees of activation of different pathways
contributing to dysmetabolic states (Fig. 2).
Modulation of CSN and CB to control:
implications in health and disease
Bioelectronic Medicine and electroceuticals-based medi-
cines target the modulation of the electricity of the body
to correct pathological conditions. This emerging and
exciting field of research is supported by the fact that
circuits made of neurons communicating through elec-
trical impulses are the main regulators of all organs’
functions (Famm et al. 2013). Device-generated brain
modulation, like deep brain electrical stimulation, trans-
cranial magnetic stimulation, and transcranial direct
current stimulation have been in clinical or exploratory
use for various neurological conditions (Cabrera et al.
2014; Famm et al. 2013; Fregni and Pascual-Leone
2007). Vagus nerve stimulation (VNS) has also been
used for the treatment of inflammatory diseases (Koop-
man et al. 2016), like IBD (Pavlov and Tracey 2015). For
example, a study reported significant clinical remission,
in five out of seven patients with Crohn’s disease, sub-
mitted to 6 months of treatment with VNS (Bonaz et al.
2016). Additionally, Koopman et al. developed the first
clinical trial using VNS to treat RA, in which a set of 17
RA patients submitted to an 84 day open-label trial re-
vealed significantly decreased TNF production and sig-
nificantly improved clinical symptoms (Koopman et al.
2016).
Modulation of vagus nerve activity for the resolution of
metabolic diseases
The use of electrical stimulation of vagus nerve applied
as a therapeutic for metabolic/inflammatory diseases
envisioned and highlighted the importance of bioelec-
tronic medicine not only for these pathologies but also
for other therapeutic applications (Birmingham et al.
2014; Dirr et al. n.d.). Homeostatic and reward signaling
of brain circuits has been implicated in obesity and
metabolic disorders together with low firing capacity of
vagal nerves (Atasoy et al. 2012; Fernandes et al. 2020;
Sternson et al. 2013) and there is an increasing interest
in the development of treatments aimed at targeting
brain regions associated with appetite behaviors (Whit-
ing et al. 2018). Neuromodulation using electrical or
chemical alterations has been applied to improve bio-
logical functions and can either stimulate or inhibit cen-
tral or peripheral autonomic nervous processes to
influence homeostatic and reward pathways associated
with metabolic diseases (Dendy et al. 2019). Regarding
electrical modulation for obesity, deep brain stimulation
has been tested in the hypothalamus, ventromedial
hypothalamus, and nucleus accumbens with promising
findings, although further research is needed to elucidate
the long-term efficacy of this therapy (Whiting et al.
2018). VNS has also been tested for obesity and meta-
bolic disorders, although there are discrepancies in the
results reported by different studies. However, it is
widely accepted that electrical stimulation of vagus nerve
benefits individuals by increasing vagus nerve signaling
pathways and increasing satiety (Pelot and Grill 2018).
In fact, vagus nerve modulation (vBloc therapy) is cur-
rently an FDA approved treatment for long-term treat-
ment of obesity in patients aged from 18 to 65 years
with a body mass index (BMI) of 40 to 45 kg/m2 or > 35
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kg/m2 and one or more obesity-related complications.
Results from the Recharge study described that after 12
months patients with vBlock activated lost 8.5% more
weight than the controls (Morton et al. 2016). Also, al-
though safe, the vblock therapy had several adverse ef-
fects such as nausea, pain at the neuroregulator site,
vomiting, and surgical complications as well as heart-
burn, problems swallowing, belching, mild nausea, and
chest pain (Morton et al. 2016). In vBloc therapy both
afferent and efferent vagal nerves are blocked and it has
been postulated that its effects are due to changes in sa-
tiety and consequent weight loss (Dendy et al. 2019;
Ikramuddin et al. 2014).
The mechanism behind vagus nerve stimulation for
the treatment of obesity and metabolic complications
has been associated with regulation of peristaltic move-
ments and distension and compression of gut and stom-
ach, respectively, with the regulation of central firing in
regions dedicated to satiety and food intake control, and
normalization of leptin resistance (de Lartigue 2016).
However, since caloric intake has been described as un-
altered in many studies that show body weight decrease
and metabolic homeostasis in other peripheral organs, it
is crucial that we understand other mechanisms that
might confer the long-term beneficial effects of vagal
electrical treatment in weight loss, glucose homeostasis
and metabolic control (Pelot and Grill 2018). On this
scenario we postulate that the previously described role
of vagal reflex on immune regulation both in peripheral
organs and brain can be responsible for some beneficial
effects of this therapeutic technique. This hypothesis has
been tested with some important and promising results
like the work of Zang et al. that showed that vagus elec-
trical stimulation decreased overall inflammation and
autonomic control of weight (Zhang et al. 2009).
CB and CSN modulation for the treatment of metabolic
diseases
As a therapeutic target, the electrical modulation of CB
chemoreceptors could also modify the inflammatory re-
sponse during sepsis syndromes through a network con-
sisting of neural - sympathetic and parasympathetic
activation and, as a consequence, cytokine elements.
Santos-Almeida et al. clearly stated that, in conscious
rats, CSN electrical stimulation (1 mA, 1 ms, 30 Hz) dur-
ing 1 h, attenuates the response to LPS by decreasing
TNF, IL-1β and IL-6 levels and increasing the levels of
IL-10, effects mediated by both sympathetic and para-
sympathetic pathways (Santos-Almeida et al. 2017). CB
electrical modulation have also been tested for metabolic
diseases, with Sacramento et al. showing that kilohertz
frequency alternating current (KHFAC) modulation, and
therefore electrical blocking applied continuously to the
CSN was able to restore after 1 week, and maintain
during 9 weeks insulin sensitivity and glucose tolerance
in an early type 2 diabetes animal model (Sacramento
et al. 2018). Moreover, the authors found that KHFAC
effects were reversible, as upon cessation of electrical
modulation insulin resistance and glucose intolerance
returned to normal values within 5 weeks (Sacramento
et al. 2018). Driving KHFAC of the CSN towards clinical
translation, Fjordbakk et al. showed in the pig that high
frequency electrical modulation of the CSN was able to
block evoked chemo-afferent responses (Fjordbakk et al.
2019). The CSN conveys not only the information that
comes from the CB but also the baroreceptor informa-
tion that comes from the carotid sinus, that is involved
in the acute adjustments of blood pressure (Marcus
et al. 2014). In fact, electrical stimulation of carotid sinus
baroreflex afferents acutely decreased arterial blood
pressure in hypertensive patients, an effect mediated
through sympathetic inhibition (Heusser et al. 2010),
with the Barostim Therapy® being approved by the FDA
to treat drug-resistant hypertension and heart failure
(FDA 2020). More recently, it was shown that electrical
carotid baroreceptor stimulation by electrodes placed
into the carotid sinus wall (10 Hz, 1 ms, stimulating cycle
with an interval of 1 min each 5 min) improves glucose
metabolism in obese rats by ameliorating adipose tissue
function, particularly the BAT (Cao et al. 2019). In con-
trast with these results, May et al. (May et al. 2014) re-
ported that in hypertensive patients baroreceptor
stimulation did not elicit significant changes in muscle
glucose delivery and whole-body insulin sensitivity, sug-
gesting that baroreflex stimulation does not affect glu-
cose metabolism and insulin action. Also, Wallbach
et al. (Wallbach et al. 2015) showed that in 30 patients
with drug-resistant hypertension (10 of those with dia-
betes) that long-term electrical stimulation of baroreflex
during 6 months did not change significantly post-
prandial glucose tolerance, fasting insulin levels, C-
peptide levels, hemoglobin A1c, HOMA-IR, HOMA-β,
ISQuickI, weight, and BMI. The differences between the
findings of Cao et al. (Cao et al. 2019) work, May et al.
and Wallbach et al. may rely on the different species
studied – human vs rat – but we can postulate that
probably in the studies of Cao et al. an interference with
the CB chemoreceptors might have occurred. In fact,
one could speculate that electrical current delivered to
the baroreceptors by Cao et al. could have affected the
CB chemoreceptors, therefore eliciting an anti-
inflammatory response from the CB that would attenu-
ate dysmetabolism. In agreement with a possible influ-
ence of CB chemoreceptors in BAT metabolism and
with the interference of CB chemoreceptors in the ef-
fects of electrical modulation of baroreceptors observed
by Cao et al. (Cao et al. 2019), it was previously shown
that activation of CB chemoreceptors inhibits the
Conde et al. Bioelectronic Medicine            (2020) 6:24 Page 14 of 20
elevated levels of BAT sympathetic nerve activity evoked
by hypothermia (Madden and Morrison 2005). To dis-
card the interference between the CB chemoreceptors
and baroreceptors Cao et al. (Cao et al. 2019) should
have evaluated basal ventilation, hypoxic ventilatory re-
sponse and the baroreflex. Although, we cannot exclude
a possible direct role of baroreceptors in attenuating in-
flammation and dysmetabolim or even a crosstalk be-
tween carotid chemo and baroreceptors in the
modulation of this immuno-metabolic link, we can cer-
tainly suggest that carotid sinus nerve electrical modula-
tion can be an approach for the treatment of metabolic
diseases.
Conclusion and perspectives
In recent decades several lines of evidence have
highlighted the possibility of using the CB as a new point
of intervention for neuroinflammation control. Support-
ing this, the CB has been described to be able to sense
several cytokines (Fernandez et al. 2014; Fernández et al.
2011; Sacramento et al. 2020) being involved in the re-
sponse to PAMPs, as LPS (Fernández et al. 2008; Kåhlin
et al. 2014; Mkrtchian et al. 2012; Nardocci et al. 2015)
and to endogenous damage-associated molecular pat-
terns (MKrtchian et al. 2020). Additionally, our group
has clearly demonstrated that the CB is a regulator of
peripheral insulin sensitivity and glucose homeostasis
and that CB dysfunction is involved in the genesis of
metabolic diseases, and postulated that the modulation
of CB/CSN activity might be used for the treatment of
metabolic diseases as obesity and type 2 diabetes (Cu-
nha-Guimaraes et al. 2020; Ribeiro et al. 2018; Ribeiro
et al. 2013; Sacramento et al. 2018; Sacramento et al.
2017). CB dysfunction in metabolic diseases is associated
with increased circulating levels of insulin (Conde et al.
2018; Cunha-Guimaraes et al. 2020; Ribeiro et al. 2013),
leptin (Caballero-Eraso et al. 2019; Ribeiro et al. 2018)
and inflammatory mediators such as cytokines released
from adipose tissue (Conde et al. 2017). These mediators
acting on the CB, via specialized receptors, modulate its
function by, for example, altering the release of neuro-
transmitters from CB type 1 cells, and therefore chan-
ging the activity of CSN, the CB sensitive nerve
(Fernandez et al. 2014; Fernández et al. 2011; Sacra-
mento et al. 2020). The CSN integrates this information
from the CB and relays afferent inputs to the NTS, lead-
ing to the activation of both sympathetic and parasym-
pathetic nervous systems that modulate metabolism
through efferent outputs to target organs, thus generat-
ing a vicious cycle between dysmetabolism and inflam-
matory pathways that we postulate to be a contributing
factor in metabolic diseases (Fig. 2).
Many of the studies that disclosed the role of CB as a
sensor of inflammation and metabolism, its role in the
genesis of metabolic diseases and the existence of an
immune-metabolic CB-brain axis relied upon surgical
ablation/resection of the CB/CSN as an experimental ap-
proach. Unilateral CB surgical resection has been tested
in the past in patients with asthma (Anderson et al.
1986) and more recently resistant hypertension (Narkie-
wicz et al. 2016), although with disappointing results
due to the lack of long-term efficacy due to CSN nerve
fiber regeneration and the appearance of side effects
(Conde 2018). Adding to this there are issues with pa-
tient compliance due the extreme nature of this invasive
procedure. Therefore, a suitable and selective thera-
peutic strategy to modulate CB function is still lacking.
Our group has however shown that continuous KHFAC
very effectively mimics the positive outcomes of CSN re-
section in terms of glucose homeostasis and insulin ac-
tion in the rat (Sacramento et al. 2018). This is an open
door for further investigation of the use of bioelectronic
medicine for the treatment of metabolic diseases. Feasi-
bility of KHFAC modulation of CSN activity has been
confirmed in the pig (Fjordbakk et al. 2019) showing its
translational potential. An advance for this kind of thera-
peutic will be the development of closed-loop neuromo-
dulation solutions to adjust in real-time the neural
activity related to dysmetabolism and re-establish, as
much as possible, the physiological conditions. Interest-
ingly, Cracchiolo et al. recently showed that CSN activity
strongly correlates with perturbations in glycaemia levels
in both control and diabetic rats, indicating that CSN ac-
tivity could serve as a marker to monitor glycaemic al-
terations and, therefore, could be used for closed-loop
control of CSN neuromodulation (Cracchiolo et al.
2019a). Such progress is of course an important contri-
bution to effective bioelectronic therapies. However, a
more detailed neuronal decode of CSN activity in differ-
ent disease states, and the characterization of the neural-
immune-metabolic circuities involving the CB in the dif-
ferent metabolic diseases, is needed to allow for select-
ive, adaptable and personalized bioelectronics therapies.
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